- Home
- EMCG vs MRNS Comparison
EMCG vs MRNS Comparison
Compare EMCG & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMCG
- MRNS
- Stock Information
- Founded
- EMCG 2021
- MRNS 2003
- Country
- EMCG United States
- MRNS United States
- Employees
- EMCG N/A
- MRNS N/A
- Industry
- EMCG
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- EMCG
- MRNS Health Care
- Exchange
- EMCG NYSE
- MRNS Nasdaq
- Market Cap
- EMCG 83.7M
- MRNS 104.7M
- IPO Year
- EMCG 2022
- MRNS 2014
- Fundamental
- Price
- EMCG $11.60
- MRNS $0.31
- Analyst Decision
- EMCG
- MRNS Buy
- Analyst Count
- EMCG 0
- MRNS 12
- Target Price
- EMCG N/A
- MRNS $4.56
- AVG Volume (30 Days)
- EMCG 3.2K
- MRNS 5.7M
- Earning Date
- EMCG 01-01-0001
- MRNS 11-05-2024
- Dividend Yield
- EMCG N/A
- MRNS N/A
- EPS Growth
- EMCG 186.72
- MRNS N/A
- EPS
- EMCG 0.24
- MRNS N/A
- Revenue
- EMCG N/A
- MRNS $30,263,000.00
- Revenue This Year
- EMCG N/A
- MRNS $21.18
- Revenue Next Year
- EMCG N/A
- MRNS $56.42
- P/E Ratio
- EMCG $48.18
- MRNS N/A
- Revenue Growth
- EMCG N/A
- MRNS 16.56
- 52 Week Low
- EMCG $10.84
- MRNS $0.26
- 52 Week High
- EMCG $13.39
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- EMCG 73.32
- MRNS 21.75
- Support Level
- EMCG $11.47
- MRNS $0.29
- Resistance Level
- EMCG $11.62
- MRNS $1.96
- Average True Range (ATR)
- EMCG 0.01
- MRNS 0.12
- MACD
- EMCG 0.01
- MRNS -0.18
- Stochastic Oscillator
- EMCG 84.62
- MRNS 2.41
About EMCG EMBRACE CHANGE ACQUISITION CORP
Embrace Change Acquisition Corp is a blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.